Cosentyx Market By Indication (Plaque Psoriasis, Ankylosing Spondylitis, Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis, Others), By Dosage Form (Prefilled Syringes, Autoinjectors, Vials), By Route of Administration (Subcutaneous, Intravenous), By Patient Demographics (Adults, Geriatrics, Pediatric), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals, Specialty Clinics, Homecare Settings), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

Industry Outlook

The Cosentyx Market accounted for USD 6.31 Billion in 2024 and is expected to reach USD 33.76 Billion by 2035, growing at a CAGR of around 16.47% between 2025 and 2035. Cosentyx is a biologic medication manufactured by Novartis that addresses all autoimmune diseases, including psoriasis, ankylosing spondylitis, and rheumatoid arthritis. The way it works is by blocking this protein called interleukin-17A, which is involved in the inflammatory process. Cosentyx should be administered through subcutaneous injections. Its importance as a treatment option is because it has produced several efficiencies in reducing inflammation and improving symptoms. Therefore, this drug is beneficial when treatment fails. Cosentyx has increased its market penetration through greater use in immunology and dermatology.

Report Scope:

Market Dynamics

Increasing prevalence of autoimmune diseases boosting market demand.

The demand for Cosentyx is further propelled by rising incidences of autoimmune diseases. Diseases like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis are gaining more prevalence in the world with consequent increasing demand for Cosentyx-like medicines. Growth in these markets has also been aided by the trend toward biologics, which provide targeted therapies with fewer side effects than traditional treatments. Increased patient education about autoimmune conditions, together with evolving tools for diagnosis, has enabled early detection and ultimately a boost in treatment adoption.

The National Institutes of Health (NIH) report that 23 million Americans suffer from autoimmune diseases, which manifests the expanding market for Cosentyx-intervening treatments. Patients seem to be looking for a long-term, effective remedy for managing these chronic conditions, ensuring that the demand for Cosentyx is likely to rise in the future. Furthermore, investments made in the healthcare sector and the availability of health insurance will transform these therapies into more available options for an increasing patient population amidst growing market prospects. The increasing burden of comorbidities associated with autoimmune diseases will also sustain demand.

Increasing investment in biologics research and development globally.

The Cosentyx market is driven by several key factors that support its growth. The increasing cases of autoimmune diseases like rheumatoid arthritis, ankylosing spondylitis, and psoriasis are pushing the craving for biologics, such as Cosentyx, for their strong efficacy as treatments. Advances in biologic research, resulting in improved effectiveness and fewer adverse effects, would improve treatment outcomes and further add to treatment alternatives available to patients.

Personalized medicine is also gaining momentum, and it presents a good market opportunity for Cosentyx because the approach tailors treatment based on genetic profile differences of individuals. This growth is attributed to the increasing investments in healthcare worldwide and the ever-increasing emphasis on biologics for chronic conditions. The most recent approval of Cosentryx has further extended the use of the drug across indications.

The growing awareness of the benefits of the drug coupled with an increase in the access of people to healthcare in emerging markets propels demand for Cosentryx. Moreover, competitive pricing strategies and strong physician and patient support programs will strengthen its market position. Ultimately, these are the interwoven market drivers on which the future success of the drug heavily relies.

Market competition from other biologic drugs and therapies.

The Cosentyx market is subject to numerous restrictions owing to competition from other biological medications or treatments. Humira and Enbrel, two of the top biological treatments for rheumatoid arthritis and psoriasis, are competitors of Cosentyx, offering essentially the same therapeutic outcomes. The FDA has authorized Rinvoq and other JAK inhibitors because of their unique modes of action and easy-to-take oral tablet formulations, which give patients a distraction.

Drug pricing issues include the emergence of inexpensive generic versions of Humira, which lessen Cosentyx's cost advantage. The market share of Cosentyx is at risk due to combination therapy and increasing personalized medicine approaches, which open new treatment possibilities. Reimbursement hurdles with complicated access pathways for patients represent barriers limiting the full adoption of the medicine. Cosentyx faces some likely challenges in the market as patients, together with healthcare providers, continue to search for medicines with fewer side effects and simpler modes of administration. Over time, changes in regulatory approvals and clinical guidelines may also affect the long-term market position of Cosentyx.

Growing collaborations and partnerships in biologics research and development.

The growing collaborations and partnerships in biologics research and development present significant opportunities for the Cosentyx market. The well-known IL-17A inhibitor Cosentyx (secukinumab) has already shown promise in treating autoimmune diseases like psoriasis, ankylosing spondylitis, and psoriatic arthritis. However, as the focus on precision medicine and customized medications increases, biotech companies, research institutions, and pharmaceutical companies are working quickly to develop Cosentyx for new uses. These partnerships could help Cosentyx expand its market reach and break into uncharted therapeutic areas like multiple sclerosis or inflammatory bowel disease.

Further, strategic alliances could lead to a global market reach, better clinical data, and expedited regulatory approvals, thus fortifying the position of Cosentyx in biologics. Such changes bring very promising prospects for the growth of Cosentyx, and this is a good part of its future. They could also keep pushing Cosentyx to increase its sales and penetration into the market since biologic therapy demand is growing in emerging markets. Cosentyx stands to benefit the most as the biologics sector goes through these transformations in internal healing modalities.

Potential market growth in emerging markets with expanding healthcare.

Cosentyx, a biologic treatment for autoimmune diseases, stands to benefit significantly from the expanding healthcare infrastructure in emerging markets. Emerging economies gain much from economic growth along with rising healthcare access and knowledge about autoimmune diseases, and the demand will continue to increase for such innovative therapies among new patients, Cosentyx being one of them. Countries in Asia, Latin America, and the Middle East invest hugely in healthcare and bring patients closer to specialized treatments.

With a rapidly increasing rate of diseases like psoriasis, ankylosing spondylitis, and rheumatoid arthritis, Cosentyx has the most shares in these markets. With the adoption of biologics growing and very favorable improvement in coverage of insurance in these regions, the opportunity for Cosentyx is fortified even more. The scope for growth will also be invigorated as middle classes in such regions will tend to increase demand for premium healthcare products, hence increasing adoption.

Strong clinical evidence, proven efficacy, and acceptance as a trusted treatment option for emerging markets further add value to the opportunity Cosentyx has. Building partnerships with local healthcare providers and governments to ease access and affordability may accelerate penetration and ensure long-term growth in these increasingly high-growth markets.

Industry Experts Opinion

"Cosentyx (secukinumab) has significantly transformed the treatment landscape for autoimmune diseases, particularly for conditions like psoriasis, ankylosing spondylitis, and psoriatic arthritis. As an IL-17A inhibitor, it effectively targets the underlying inflammatory processes, providing patients with relief from chronic symptoms and improving their quality of life. The drug's precision mechanism of action offers hope for patients who previously struggled with limited treatment options."

• Dr. Sarah Collins, MD, Rheumatologist and Immunology Expert.

Segment Analysis

Based on the Indication, the Cosentyx Market is classified into Plaque Psoriasis, Ankylosing Spondylitis, Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis, and Others. Plaque psoriasis is the most significant and dominant segment in the Cosentyx market. This condition has the greatest patient population among the indications for Cosentyx, accounting for a significant amount of sales and market share for the drug. The high efficacy of Cosentyx in moderate-to-severe plaque psoriasis has since fueled its strong acceptance as a mainstay therapy. An unmet need and an unceasing condition render demand in favor of Cosentyx in this segment. The high efficacy in symptom relief and quality of life enhances the position of Cosentyx in this market.

Based on the Dosage Form, the Cosentyx Market is classified into Prefilled Syringes, Autoinjectors, and Vials. In the Cosentyx market, autoinjectors are the most significant and dominant dosage form. This segment has gained dominance in providing patient convenience and ease of use for self-administration at home. This user-friendly design enhances patient compliance, especially in chronic scenarios, such as psoriasis and ankylosing spondylitis. It also offers accurate dosing with very little healthcare provider intervention, which has stimulated its uptake. Therefore, it is highly preferred by both patients and medical experts, which significantly affects Cosentyx's market share.

Regional  Analysis

The North American Cosentyx market is growing significantly, supported by the increasing prevalence of autoimmune diseases such as psoriasis, ankylosing spondylitis, and rheumatoid arthritis. Cosentyx is one of the leading biologic therapies and gained a hefty market share due to its efficacy, long-term safety profile, and ease of administration for the patients. Among all the countries in North America, the U.S. holds the largest share, supported by an advanced healthcare infrastructure and a comparatively high adoption rate of newer treatment modalities. On a small scale, Canada is also showing steady demand. With the mounting interest in personalized medicine and biologics, Cosentyx is becoming increasingly favored by healthcare providers for treating chronic inflammatory diseases.

The competitive force from other biologics and biosimilars, along with changing reimbursement mechanisms, often leads to quite dynamic market situations. Early diagnosis and rapid introduction of treatment are the emerging trends expected to crystallize this market growth further. Awareness of autoimmune disorders is further developing, assisted by the increasing number of clinical trials supporting the use and wider acceptance of Cosentyx in North America.

The Asia Pacific Cosentyx market is progressively accelerating because of the rising incidence of autoimmune illnesses and the growing focus on cutting-edge biological treatment alternatives in the medical field. China, South Korea, and India are the main markets, with Japan leading the way because of its strong healthcare system and established biologics regulations. Cosentyx in opening markets like India and Southeast Asia is witnessing a slower process but soon would accelerate as healthcare access improves and awareness regarding autoimmune conditions increases.

The increasing number of clinical trials and the investments made in the healthcare sector have also been found to be contributory to the market. While Cosentyx faces competition from a large number of local and international biosimilars, it continues to register its advantages regarding well-established treatments for chronic inflammatory diseases. Moreover, some countries have also made it easier to acquire through reimbursement policies, further hindering competition. Adoption and demand for Cosentyx are expected to keep expanding over the next few years as advanced treatment becomes popular among patients.

Competitive Landscape

Different biologics for autoimmune and inflammatory conditions are the targets of high competition in the Cosentyx market. Novartis, the parent company of Cosentyx, remains a dominant force, while companies like AbbVie with Rinvoq and Janssen Pharmaceuticals with Tremfya continue to vie for an equal share. The developments have included Amgen's further work on its IL-23 inhibitor pipeline and Bristol-Myers Squibb's ongoing advancements with its candidates for autoimmune diseases. Further, markets of new biologics and biosimilars are being explored by Pfizer, Eli Lilly, and Merck & Co. Thus, the competition becomes fierce. With UCB's antibody therapies vying for market share against Merck's Tremfya or Pfizer's Ablynx, complexifying market dynamics, Regeneron has also been making inroads in inflammatory disease. Ongoing innovations are advocating more treatment choices and more competition with an overall prospect of better patient outcomes.

Cosentyx Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In October 2023, the U.S. Food and Drug Administration (FDA) approved Cosentyx for treating moderate to severe hidradenitis suppurativa in adults. This approval became the first new biologic treatment option for the condition in almost ten years. It provided a significant advancement in available therapies. Cosentyx's approval marked a milestone for hidradenitis suppurativa treatment.
• In October 2023, Novartis received FDA approval for an intravenous (IV) formulation of Cosentyx, broadening treatment options for adults with rheumatic diseases. This approval marked the introduction of the first IV formulation targeting interleukin-17A for these conditions.

Frequently Asked Questions (FAQs)